Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

Video

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

A. Keith Stewart, MB ChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

In other studies, carfilzomib has been linked to heart-related adverse events, including swelling, shortness of breath, and cardiac failure, according to Stewart. However, in the phase III ASPIRE trial, which studied carfilzomib in combination with lenalidomide and dexamethasone, it was shown that the addition of the carfilzomib did not significantly change the frequency or severity of adverse events.

With carfilzomib, the number of adverse events was slightly higher, but there was only a modest increase in cardiac failure. Also, serious events did not increase significantly in the trial.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD